Filing Flows

Filing Flows › 8-K events › Zymeworks

Zymeworks: results of operations

Form 8-K filed Nov 9, 2026 · items 2.02, 7.01

Results of operationsZymeworks Provides Corporate Update and

What the filing says

• 2026 financial guidance raised to a total revenue range of $337 million to $351 million (previously between $278 million and $292 million) and an Adjusted EBITDA range of $176 million to $190 mi llion (previously between $114 mill ion and $128 million) • Ziihera ® first-line advanced gastroesophageal adenocarcinoma (

ScaleThe filing names $351.0M: about 34% of Zymeworks' annual revenue ($1.03B, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 69,249 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Zymeworks at a glance

Latest quarterQ3 2026
Revenue$256.5M
Revenue Y/Y+829%
Operating margin69.2%
IndustryPharmaceutical Preparations

Zymeworks, Q3 2026: revenue $256M (+829% year over year), operating margin 69.2%. The chart follows the revenue to costs, profit and cash.

Zymeworks: every quarter, Q/Q and Y/Y, holders and guidance →

Zymeworks’s other material 8-Ks

Other recent guidance

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.